Hong Kong is bolstering its efforts to combat human papillomavirus (HPV), a virus linked to several cancers, through a multi-pronged approach. The region is reporting a sustained 90% vaccination rate among children and is now expanding access with the rollout of its first domestically produced vaccine[[1]]. In addition to increased vaccination opportunities, Hong Kong is pioneering more accessible screening methods, including self-sampling options, to improve early detection and prevention of HPV-related diseases[[2]]. HPV can be transmitted through skin-to-skin contact, and while frequently enough asymptomatic, can lead to serious health issues in both men and women[[1]].
Hong Kong Sees High HPV Vaccination Rates, Introduces Self-Sampling and Domestic Vaccine
Hong Kong is maintaining approximately a 90% vaccination rate for the human papillomavirus (HPV) vaccine among children following its inclusion in the childhood immunization program. This high uptake underscores the importance of preventative measures against HPV-related cancers and diseases.
In addition to the established program, the first batch of domestically produced quadrivalent HPV vaccines has recently become available. This development expands options for HPV vaccination within the region.
Alongside increased vaccine access, Hong Kong is also introducing self-sampling HPV screening. The “Happy Cervix” station is expected to launch this service in the first quarter of the current year, offering a more accessible method for cervical cancer screening. To date, approximately 48,000 doses of the HPV vaccine have been administered through catch-up programs.
HPV infections can lead to cervical cancer, as well as other cancers like penile cancer, highlighting the importance of vaccination for both males and females. Experts emphasize that vaccination is a key strategy in reducing the risk of developing these cancers.
The vaccination period for adolescents is also being extended, providing a wider window for individuals to receive the preventative vaccine. This extension aims to maximize protection against HPV-related illnesses.
